Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

被引：0
|
作者：
Yu, L. [1 ]
Xu, J. [1 ]
Qiao, R. [1 ]
Zhong, H. [1 ]
Han, B. [1 ]
Zhong, R. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
small-cell lung cancer; anlotinib; PD-1/PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S391 / S392
页数：2
相关论文
共 50 条
  • [31] Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
    Jin, Chen-xing
    Liu, Yan-song
    Qin, He-nan
    Teng, Yi-bin
    Sun, Rui
    Ma, Zhong-jing
    Wang, A-man
    Liu, Ji-wei
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [32] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [33] Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors
    Mohammed, Nader
    Zhou, Rong Rong
    Xiong, Zeng
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1127):
  • [34] Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel with or without bevacizumab as second-line therapy or beyond for patients with metastatic non-small-cell lung cancer.
    Zhang, Fan
    Li, Tao
    Zhang, Yuzi
    Cai, Shangli
    Zhao, Lei
    Jiao, Shun Chang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Xia, Liliang
    Liu, Yuanyong
    Wang, Ying
    ONCOLOGIST, 2019, 24 : S31 - S41
  • [36] Albumin-bound paclitaxel plus PD-1/PD-L1 inhibitor versus second-line chemotherapy for patients with recurrent small cell lung cancer.
    Mu, Fengchun
    Fan, Bingjie
    Li, Butuo
    Qin, Wenru
    Fan, Xinyu
    Wang, Shijiang
    Wang, Chunni
    Zou, Bing
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer
    Mo, Dun-Chang
    Liang, Zi-Yu
    Chen, Long
    Huang, Jian-Feng
    Luo, Peng-Hui
    Wang, Han-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)
  • [38] Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
    Ai, Leilei
    Chen, Jian
    Yan, Hao
    He, Qiaojun
    Luo, Peihua
    Xu, Zhifei
    Yang, Xiaochun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3625 - 3649
  • [39] Combination of PD-1/PD-L1 checkpoint blockade and dendritic cell therapy
    Nesselhut, J.
    Marx, D.
    Lange, H.
    Chang, R. Y.
    Nesselhut, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 : 95 - 95
  • [40] Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer A Review
    Sacher, Adrian G.
    Gandhi, Leena
    JAMA ONCOLOGY, 2016, 2 (09) : 1217 - 1222
12345